<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1774">
  <stage>Registered</stage>
  <submitdate>5/12/2007</submitdate>
  <approvaldate>5/12/2007</approvaldate>
  <nctid>NCT00569400</nctid>
  <trial_identification>
    <studytitle>Comparison of Human Insulin Produced by the Current Process and the NN729 Process in Type 1 Diabetes</studytitle>
    <scientifictitle>Comparison of Efficacy and Safety of Human Insulin Produced by the Current Process and the NN729 Process in Type 1 Diabetes Mellitus</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>NN729-1541</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Diabetes</healthcondition>
    <healthcondition>Diabetes Mellitus, Type 1</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - human insulin

Treatment: drugs: human insulin


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change of human insulin antibodies</outcome>
      <timepoint>after 26 weeks of treatment</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Change of human insulin antibodies</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Frequency of adverse events</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Duration of diabetes for at least 12 months

          -  Basal/bolus treatment with human insulin for at least 2 months preceding trial start

          -  Body Mass Index (BMI) lesser than or equal to 35.0 kg/m2

          -  HbA1c lesser than or equal to 12.0%</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Proliferative retinopathy or maculopathy requiring acute treatment or laser treatment
             within the last 6 months

          -  Any condition that the investigator and/or sponsor feel would interfere with trial
             participation

          -  Known or suspected allergy against trial product or related products</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/05/2003</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>241</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>19/01/2004</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,SA</recruitmentstate>
    <hospital>Novo Nordisk Investigational Site - Broadmeadow</hospital>
    <hospital>Novo Nordisk Investigational Site - Keswick</hospital>
    <hospital>Novo Nordisk Investigational Site - Dunedin</hospital>
    <hospital>Novo Nordisk Investigational Site - Hamilton</hospital>
    <hospital>Novo Nordisk Investigational Site - Kippa Ring</hospital>
    <hospital>Novo Nordisk Investigational Site - Miranda</hospital>
    <hospital>Novo Nordisk Investigational Site - Stones Corner</hospital>
    <postcode>2292 - Broadmeadow</postcode>
    <postcode>5035 - Keswick</postcode>
    <postcode>NZ - Dunedin</postcode>
    <postcode>NZ - Hamilton</postcode>
    <postcode>4021 - Kippa Ring</postcode>
    <postcode>2228 - Miranda</postcode>
    <postcode>4120 - Stones Corner</postcode>
    <countryoutsideaustralia>
      <country>Hong Kong</country>
      <state>Shatin, New Territories</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Malaysia</country>
      <state>Cheras</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Malaysia</country>
      <state>Georgetown, Penang</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Malaysia</country>
      <state>Kota Bharu, Kelantan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Philippines</country>
      <state>Cebu City</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Philippines</country>
      <state>Iloilo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Philippines</country>
      <state>Makati City</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Philippines</country>
      <state>Marikina City</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Novo Nordisk A/S</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This trial is conducted in Asia and Oceania. The aim of this trial is to compare the efficacy
      and safety of human insulin produced by the current process and the NN729 process in type 1
      diabetes.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00569400</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Global Clinical Registry (GCR, 1452)</name>
      <address>Novo Nordisk A/S</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>